spondylometaphyseal dysplasia, Schmidt type
diseaseOn this page
Also known as spondylometaphyseal dysplasia Algerian typespondylometaphyseal dysplasia Schmidt typespondylometaphyseal dysplasia with severe genu valgumspondylometaphyseal dysplasia, Algerian type
Summary
spondylometaphyseal dysplasia, Schmidt type (MONDO:0008478) is a disease with 1 cohort gene.
At a glance
- Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
- Cohort genes: 1
- ClinVar variants: 5
- Phenotypes (HPO): 30
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Cases/families | 7 | Worldwide | Validated | |
| Point prevalence | <1 / 1 000 000 | Worldwide | Validated |
Signs & symptoms
Clinical features (HPO)
30 HPO clinical features (Orphanet curated; top 30 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000925 | Abnormality of the vertebral column | Very frequent (80-99%) |
| HP:0000944 | Abnormal metaphysis morphology | Very frequent (80-99%) |
| HP:0100255 | Metaphyseal dysplasia | Very frequent (80-99%) |
| HP:0000926 | Platyspondyly | Frequent (30-79%) |
| HP:0001385 | Hip dysplasia | Frequent (30-79%) |
| HP:0002650 | Scoliosis | Frequent (30-79%) |
| HP:0002812 | Coxa vara | Frequent (30-79%) |
| HP:0002815 | Abnormality of the knee | Frequent (30-79%) |
| HP:0002857 | Genu valgum | Frequent (30-79%) |
| HP:0002867 | Abnormality of the ilium | Frequent (30-79%) |
| HP:0003375 | Narrow greater sciatic notch | Frequent (30-79%) |
| HP:0003510 | Severe short stature | Frequent (30-79%) |
| HP:0003521 | Disproportionate short-trunk short stature | Frequent (30-79%) |
| HP:0010574 | Abnormality of the epiphysis of the femoral head | Frequent (30-79%) |
| HP:0100866 | Short iliac bones | Frequent (30-79%) |
| HP:0000185 | Cleft soft palate | Occasional (5-29%) |
| HP:0000347 | Micrognathia | Occasional (5-29%) |
| HP:0000402 | Stenosis of the external auditory canal | Occasional (5-29%) |
| HP:0000545 | Myopia | Occasional (5-29%) |
| HP:0001561 | Polyhydramnios | Occasional (5-29%) |
| HP:0002020 | Gastroesophageal reflux | Occasional (5-29%) |
| HP:0002033 | Poor suck | Occasional (5-29%) |
| HP:0002751 | Kyphoscoliosis | Occasional (5-29%) |
| HP:0003019 | Abnormality of the wrist | Occasional (5-29%) |
| HP:0003026 | Short long bone | Occasional (5-29%) |
| HP:0003796 | Irregular iliac crest | Occasional (5-29%) |
| HP:0008833 | Irregular acetabular roof | Occasional (5-29%) |
| HP:0011470 | Nasogastric tube feeding in infancy | Occasional (5-29%) |
| HP:0011471 | Gastrostomy tube feeding in infancy | Occasional (5-29%) |
| HP:0100864 | Short femoral neck | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | spondylometaphyseal dysplasia, Schmidt type |
| Mondo ID | MONDO:0008478 |
| MeSH | C535794 |
| OMIM | 184253 |
| Orphanet | 93316 |
| DOID | DOID:0112296 |
| ICD-11 | 1092012084 |
| SNOMED CT | 719304005 |
| UMLS | C1866688 |
| MedGen | 356595 |
| GARD | 0000504 |
| Is cancer (heuristic) | no |
Also known as: spondylometaphyseal dysplasia Algerian type · spondylometaphyseal dysplasia Schmidt type · spondylometaphyseal dysplasia with severe genu valgum · spondylometaphyseal dysplasia, Algerian type · spondylometaphyseal dysplasia, Schmidt type
Data availability: 5 ClinVar variants · 1 GenCC gene-disease record.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › skeletal dysplasia › spondylometaphyseal dysplasia › spondylometaphyseal dysplasia, Schmidt type
Related subtypes (18): Kniest dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondylometaphyseal dysplasia, Kozlowski type, spondylometaphyseal dysplasia, ‘corner fracture’ type, spondylometaphyseal dysplasia, Sedaghatian type, spondylometaphyseal dysplasia, Golden type, axial spondylometaphyseal dysplasia, spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome, Spondyloenchondrodysplasia with immune dysregulation, spondylometaphyseal dysplasia-cone-rod dystrophy syndrome, spondylometaphyseal dysplasia, A4 type, spondylometaphyseal dysplasia, East African type, autosomal recessive spondylometaphyseal dysplasia, Megarbane type, spondylometaphyseal dysplasia, Czarny-Ratajczak type, regressive spondylometaphyseal dysplasia, spondylometaphyseal dysplasia, pagnamenta type, odontochondrodysplasia, SBDS-related severe neonatal spondylometaphyseal dysplasia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
5 retrieved; paginated sample, class counts are floors:
2 pathogenic/likely pathogenic, 2 likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 197564 | NM_001844.5(COL2A1):c.3275G>A (p.Gly1092Asp) | COL2A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3600313 | NM_001844.5(COL2A1):c.2582G>T (p.Gly861Val) | COL2A1 | Pathogenic | no assertion criteria provided |
| 988569 | NM_001844.5(COL2A1):c.2059G>A (p.Gly687Ser) | COL2A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4796517 | NM_001844.5(COL2A1):c.2464-2A>T | COL2A1 | Likely pathogenic | criteria provided, single submitter |
| 4796588 | NM_001844.5(COL2A1):c.2957C>T (p.Pro986Leu) | COL2A1 | Likely pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 46 · Orphanet: 18 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| COL2A1 | Definitive | Autosomal dominant | spondyloepiphyseal dysplasia with metatarsal shortening | 46 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| COL2A1 | Orphanet:137678 | Spondyloepiphyseal dysplasia with metatarsal shortening |
| COL2A1 | Orphanet:166100 | Autosomal dominant otospondylomegaepiphyseal dysplasia |
| COL2A1 | Orphanet:1856 | Spondyloperipheral dysplasia-short ulna syndrome |
| COL2A1 | Orphanet:209867 | Autosomal dominant rhegmatogenous retinal detachment |
| COL2A1 | Orphanet:2380 | Legg-Calvé-Perthes disease |
| COL2A1 | Orphanet:459051 | Spondyloepiphyseal dysplasia, Stanescu type |
| COL2A1 | Orphanet:485 | Kniest dysplasia |
| COL2A1 | Orphanet:85166 | Platyspondylic dysplasia, Torrance type |
| COL2A1 | Orphanet:85198 | Dysspondyloenchondromatosis |
| COL2A1 | Orphanet:86820 | Familial avascular necrosis of femoral head |
| COL2A1 | Orphanet:90653 | Stickler syndrome type 1 |
| COL2A1 | Orphanet:93279 | Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis |
| COL2A1 | Orphanet:93296 | Achondrogenesis type 2 |
| COL2A1 | Orphanet:93297 | Hypochondrogenesis |
| COL2A1 | Orphanet:93315 | Spondylometaphyseal dysplasia, ‘corner fracture’ type |
| COL2A1 | Orphanet:93316 | Spondylometaphyseal dysplasia, Schmidt type |
| COL2A1 | Orphanet:93346 | Spondyloepimetaphyseal dysplasia congenita, Strudwick type |
| COL2A1 | Orphanet:94068 | Spondyloepiphyseal dysplasia congenita |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| COL2A1 | HGNC:2200 | ENSG00000139219 | P02458 | Collagen alpha-1(II) chain | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| COL2A1 | Collagen alpha-1(II) chain | Type II collagen is specific for cartilaginous tissues. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| COL2A1 | Other/Unknown | no | Fib_collagen_C, VWF_dom, Collagen |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| cartilage tissue | 1 |
| corpus epididymis | 1 |
| tibia | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| COL2A1 | 145 | broad | marker | tibia, cartilage tissue, corpus epididymis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| COL2A1 | 2,491 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| COL2A1 | P02458 | 11 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Fibronectin matrix formation | 1 | 571.0× | 0.008 | COL2A1 |
| MET activates PTK2 signaling | 1 | 380.7× | 0.008 | COL2A1 |
| Collagen chain trimerization | 1 | 259.6× | 0.008 | COL2A1 |
| Signaling by PDGF | 1 | 253.8× | 0.008 | COL2A1 |
| NCAM1 interactions | 1 | 248.3× | 0.008 | COL2A1 |
| Developmental Lineage of Pancreatic Ductal Cells | 1 | 228.4× | 0.008 | COL2A1 |
| Assembly of collagen fibrils and other multimeric structures | 1 | 200.3× | 0.008 | COL2A1 |
| Collagen degradation | 1 | 175.7× | 0.008 | COL2A1 |
| Collagen biosynthesis and modifying enzymes | 1 | 170.4× | 0.008 | COL2A1 |
| Non-integrin membrane-ECM interactions | 1 | 154.3× | 0.008 | COL2A1 |
| ECM proteoglycans | 1 | 150.3× | 0.008 | COL2A1 |
| Integrin cell surface interactions | 1 | 134.3× | 0.008 | COL2A1 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 1 | 87.2× | 0.011 | COL2A1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| otic vesicle development | 1 | 2808.7× | 0.002 | COL2A1 |
| anterior head development | 1 | 2808.7× | 0.002 | COL2A1 |
| cartilage development involved in endochondral bone morphogenesis | 1 | 2407.4× | 0.002 | COL2A1 |
| proteoglycan metabolic process | 1 | 1872.4× | 0.002 | COL2A1 |
| notochord development | 1 | 1685.2× | 0.002 | COL2A1 |
| limb bud formation | 1 | 1532.0× | 0.002 | COL2A1 |
| embryonic skeletal joint morphogenesis | 1 | 1532.0× | 0.002 | COL2A1 |
| cartilage condensation | 1 | 766.0× | 0.004 | COL2A1 |
| tissue homeostasis | 1 | 561.7× | 0.004 | COL2A1 |
| cellular response to BMP stimulus | 1 | 561.7× | 0.004 | COL2A1 |
| endochondral ossification | 1 | 543.6× | 0.004 | COL2A1 |
| extrinsic apoptotic signaling pathway in absence of ligand | 1 | 468.1× | 0.004 | COL2A1 |
| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 411.0× | 0.004 | COL2A1 |
| heart morphogenesis | 1 | 374.5× | 0.005 | COL2A1 |
| chondrocyte differentiation | 1 | 300.9× | 0.005 | COL2A1 |
| inner ear morphogenesis | 1 | 300.9× | 0.005 | COL2A1 |
| cartilage development | 1 | 251.5× | 0.005 | COL2A1 |
| roof of mouth development | 1 | 247.8× | 0.005 | COL2A1 |
| collagen fibril organization | 1 | 224.7× | 0.006 | COL2A1 |
| skeletal system development | 1 | 125.8× | 0.010 | COL2A1 |
| central nervous system development | 1 | 115.4× | 0.010 | COL2A1 |
| sensory perception of sound | 1 | 100.9× | 0.011 | COL2A1 |
| regulation of gene expression | 1 | 83.4× | 0.013 | COL2A1 |
| visual perception | 1 | 79.5× | 0.013 | COL2A1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| COL2A1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| COL2A1 | 2 | Binding:2 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | COL2A1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| COL2A1 | 2 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: COL2A1